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In the last decades, a trend towards a worldwide aging 
has been reported and diseases which are common in the 
elderly people would have important implications in clinical 
practice. Aortic stenosis (AS) is perhaps the most common 
and most often cause of sudden death among valvular heart 
diseases.[1] Its prevalence is low among adults aged < 60 
years, but increases to almost 10% in adults ≥ 80 years.[2] 
Since the degenerative calcific disease represents the lead-
ing cause of AS in developed countries, the improved un-
derstanding on its pathogenesis (atherosclerotic processes 
and/or skeleton key) may offer potentially new targets for 
preventing and inhibiting AS development and progres-
sion.[3] Patients with AS are generally asymptomatic for a 
prolonged period and the development of symptoms is a 
critical point in the natural history. Indeed, the prognosis 
changes dramatically with the onset of symptoms of angina, 
syncope or heart failure. Attention must to be given to older 
adults who, typically having decreased activity levels, tend 
to experience a delayed onset of symptoms or to relate their 
symptoms to other coexisting conditions.[4] Aortic valve 
replacement (AVR) is the gold standard therapy for severe 
symptomatic AS. However, a substantial number of patients 
with clear indications are not referred to the surgery. In a 
recently published multicenter survey (involving near one 
thousand of patients, coming from 10 centres of various size 
and geographic distribution), only one-half of the patients 
who met the criteria for clinically severe AS was referred to 
a cardiothoracic surgeon (CTS) for a preliminary evaluation 
and, of these, 41% effectively underwent AVR. Trends 
were similar across all the institutions. Referral to the CTS 
was more likely in the setting of symptoms of angina (rather 
than heart failure or syncope) and elevated echocardio-
graphic gradients (rather than low valve area). Many pa-
tients who could benefit from AVR do not undergo evalua-
tion for the global clinical condition or family refusal. The 
          
*Correspondence to: khalilfattouch@hotmail.com 
one-year survival was 94% ± 2% for operated patients vs. 
69% ± 3% for non-operated patients.[5] Invasive approaches 
should not be however denied to the older patient on the 
basis of age alone. Interestingly, Di Eusanio, et al.[6] have 
recently reported excellent contemporary outcomes in a 
population of 638 octogenarians patients (mean log-Euro-
SCORE 13.0%) underwent to conventional AVR. Overall 
hospital mortality and stroke rates were 4.5% and 1.3%, 
respectively. At six years, octogenarians' survival rate was 
similar to the expected survival of the age- and sex-matched 
regional population. Independent risk factors for decreased 
six years’ survival were renal insufficiency (preoperative 
creatinine > 2.1), extra-cardiac arteriopathy and peripheral 
neurological dysfunction.[6] Moreover, there are increasing 
evidences regarding the potential benefits of minimally in-
vasive surgical procedures (MIS) in AS. Apart better aes-
thetic results, MIS could indeed offer several advantages 
over conventional full sternotomy (FS) AVR, aiming to 
reduce trauma and to achieve decreased postoperative pain 
and ventilation time, less blood loss and faster recovery. 
Current evidence suggests that MIS is associated with ex-
cellent early and late outcomes that are at least comparable 
to FS. Progressive technical improvements (facilitated by 
the development of sutureless or rapid deployment prosthe-
ses)[7,8] may further reduce operative times durations and 
continue to increase its clinical application[9,10] Whether 
strongest long-term follow-up, randomized studies and reg-
istry data are still required to assess the durability and 
long-term outcomes, perspective of MIS-AVR in elderly 
patients should be carefully evaluated. Transcatheter aortic 
valve replacement (TAVR) has also expanded the propor-
tion of patients with AS who are candidates for valve re-
placement. Indeed, it has been shown to be a viable alter-
native treatment modality for patients previously deemed 
in-operable.[11] Being patient selection for TAVR still now 
one of the most challenging issues in clinical practice, geri-
atricians should be part of Heart Team and overall frailty 
474 Fattouch K, et al. Aortic valve stenosis in elderly patients   
 
Journal of Geriatric Cardiology | jgc@jgc301.com; http://www.jgc301.com 
(combination of ageing, disease and risk factors making 
people vulnerable) carefully evaluated.[12] In this new era 
with expanded treatment options, symptomatic patients who 
remain untreated after referral for TAVR experience a mor-
tality rate of 39% at one year.[13] Recently reported data, 
suggested good outcomes even in selected population of 
very older patients (> 85 years)[14] The results of the Pegaso 
Registry have showed that octogenarians (84.2 ± 3.5 years) 
symptomatic for severe AS are frequently managed conser-
vatively. Older age, logistic EuroSCORE, Katz index A, 
maximum gradient, pulmonary artery pressure, and reduced 
left ventricle ejection fraction were predictive factors for the 
absence of surgery (TAVI or conservative management). 
The planned conservative management was associated with 
a poor prognosis [TAVI, HR = 0.68 (95% CI: 0.49−0.93; 
P = 0.016) and AVR, HR = 0.56 (95% CI: 0.39−0.8; P = 
0.002)].[15] In high-risk patients with “temporary” contrain-
dication to AVR or TAVR, percutaneous balloon aortic 
valvuloplasty  could be safely used as a bridging inter-
vention procedure (bridge-to-decision) and the short- term 
procedural and clinic outcomes are satisfactory.[16,17] Along 
with a provision of a detailed overview of the current litera-
ture regarding the improved understanding on patho-
physiology of AS and its clinical implications, this special 
issue will address specific consideration of treatment op-
tions especially in elderly high-risk patients. 
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